These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6408288)

  • 21. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1).
    Ye Z; Kageshita T; Ishihara T; Ito S; Ono T
    J Dermatol; 1995 May; 22(5):370-5. PubMed ID: 7673560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Free and bound 5-S-cysteinyldopa and dopa in human malignant melanomas.
    Agrup G; Hansson C; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1978; 58(3):270-2. PubMed ID: 78645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative analysis of eumelanin and pheomelanin in human malignant-melanoma tissues.
    Morishima T; Fukuda E
    Arch Dermatol Res; 1985; 277(3):248-50. PubMed ID: 4015188
    [No Abstract]   [Full Text] [Related]  

  • 24. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
    Paul E; Graef V; Ruppel R; Hellwich M
    Z Hautkr; 1983 Feb; 58(4):262-5. PubMed ID: 6405551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
    Inoi T; Mojamdar M; Ichihashi M; Mishima Y
    Nihon Hifuka Gakkai Zasshi; 1982 Sep; 92(10):1065-9. PubMed ID: 6821170
    [No Abstract]   [Full Text] [Related]  

  • 26. Glutathionedopa in malignant melanoma.
    Agrup G; Falck B; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1977; 57(3):221-2. PubMed ID: 71825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible case for false-positive reaction in serum 5-S-cysteinyldopa levels in a patient with malignant melanoma by ingestion of Agaricus blazei Murrill extract.
    Konishi H; Yamanaka K; Mizutani H
    J Dermatol; 2010 Aug; 37(8):773-5. PubMed ID: 20649730
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
    Agrup G; Hafström L; Jönsson PE; Rorsman H
    Lakartidningen; 1978 Dec; 75(49):4599-600. PubMed ID: 364213
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery].
    Inoi T; Mojamdar M; Ichihashi M; Mishima Y
    Nihon Hifuka Gakkai Zasshi; 1984 Jan; 94(1):39-43. PubMed ID: 6433083
    [No Abstract]   [Full Text] [Related]  

  • 30. 5-S-cysteinyldopa in urine and tumors.
    Hara H; Chino K; Kawanami T; Sameshima T; Morishima T
    J Dermatol; 1992 Nov; 19(11):806-8. PubMed ID: 1293167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myxoid malignant melanoma. Report of three cases and review of the literature.
    Olinici CD; Vasiu R
    Morphol Embryol (Bucur); 1989; 35(4):285-7. PubMed ID: 2533968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formaldehyde-induced fluorescence method for touch preparations from amelanotic melanoma tissues: a simple and rapid method for the demonstration of melanogenic activities of amelanotic melanoma cells.
    Morishima T; Nagashima N
    Acta Derm Venereol; 1983; 63(5):418-21. PubMed ID: 6197841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the occurrence of cysteinyldopa and dopa in melanocytes and benign nevi cells.
    Falck B; Jacobsson S; Lindvall O; Nietsche UB
    Scand J Plast Reconstr Surg; 1976; 10(3):185-8. PubMed ID: 1053447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas.
    Marnot D; Decaux F; Berthelot P; Kalis B; Jardillier JC; Warren L
    Cancer Detect Prev; 1983; 6(1-2):303-10. PubMed ID: 6411338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A newly established melanoma cell line (GAK) with 5-S-cysteinyldopa phenotype].
    Nozawa S; Ohta H; Tsukazaki K; Udagawa Y; Kurihara S; Kano S
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jun; 36(6):883-92. PubMed ID: 6431036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amelanotic lentigo maligna melanoma manifesting as a dermatitislike plaque.
    Borkovic SP; Schwartz RA
    Arch Dermatol; 1983 May; 119(5):423-5. PubMed ID: 6847222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Excretion of 5-S-cysteinyldopa in the urine of Japanese patients with malignant melanoma--a helpful biochemical marker for assessing the progression of disease].
    Hanawa S
    Nihon Hifuka Gakkai Zasshi; 1983 Mar; 93(4):433-42. PubMed ID: 6411952
    [No Abstract]   [Full Text] [Related]  

  • 38. Verrucous malignant melanoma.
    Steiner A; Konrad K; Pehamberger H; Wolff K
    Arch Dermatol; 1988 Oct; 124(10):1534-7. PubMed ID: 2971338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignant melanoma--a review: early diagnosis is the key.
    Higgins E; du Vivier A
    Br J Clin Pract; 1991; 45(2):109-15. PubMed ID: 1793695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Urinary 5-S-cysteinyldopa levels in patients with malignant melanoma. Preliminary results].
    Césarini JP; Meunier M
    Rev Prat; 1975 Nov; 25(51):4037-9. PubMed ID: 1209143
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.